N/A N=15 Treatment

Mucinex® for Treatment of Filamentary Keratitis

Filamentary Keratitis

Bottom Line

View on ClinicalTrials.gov: NCT02859246 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Feb 2020

Primary outcome: Primary: Change in Number of Corneal Filaments — 5.8; 2.1 corneal filaments — p=<0.04

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Mucinex® (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Massachusetts Eye and Ear Infirmary
Primary completion: Jul 2018

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Number of Corneal Filaments	5.8; 2.1	<0.04 sig
SECONDARY Change in OSDI Score	55.6; 46.1	< 0.2

Summary

It is a pilot study aimed to determine if oral Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis.

Eligibility Criteria

Inclusion Criteria

Patients with filamentary keratitis
18 years and older

Exclusion Criteria

Active ocular surface infection of any type
Recent ocular surgery (<30 days) history of nephrolithiasis as Mucinex® has been associated in rare cases of development of kidney stones
Schirmer's test<3mm
History of hypersensitivity to Mucinex®
Concurrent eye disease requiring immediate initiation of a new treatment (e.g. topical steroids) restriction for water intake can exacerbate the risk of nephrolithiasis.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02859246). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.